Mergers and acquisitions in the pharmaceutical sector since the last 10years to cope with the mutations of this sector.
1. The pharmaceutical sector p.6
1.1. Introduction of the pharmaceutical sector
1.2 The actual pharmaceutical market
1.3 The actors of the pharmaceutical market
1.4 The strategic segmentation of the pharmaceutical market
2. The strict rules of the pharmaceutical sector in the world. p.12
2.1 Who runs the pharmaceutical industry ?
2.2. Why merging ?
3. Mergers in the market p.14
3.1 Different types of mergers in the pharmaceutical industry 3.2 Mergers and acquisitions process
3.3 Main strategic reasons
a) Financial reasons
b) Offensive reasons
c) Defensive reasons
d) Other reasons
4. The example of Pfizer’s take-over on Wyeth p.19
During the first two years of my studies, the international marketing file represents a determining exercise of our business training. Indeed, this dissertation takes the form of a global report of our theoretical knowledge and techniques. Through this internal audit, we have the opportunity to use our capacities to analyse the world of this sector, its working policies and its stakes.
Within the framework of this file, my attention went on a powerful sector of the worldwide economy, but which is not a very recurring sector in the exercises of analysis of our training: the pharmaceutical industry.
This area seems worthy review because this sector is under-research every year in many countries, for example there are research by Joel Lexchin, associate professor School of Health Policy and Management, York University, Toronto ( Drugs of Choice: A Formulary for General Practice), Lisa A Bero, professor, Department of Clinical Pharmacy and Institute for Health Policy Studies, University of California at San Francisco(Financial Ties and Conflicts of Interest Between Pharmaceutical and Tobacco Companies. Journal of the American Medical Association, 2002), Benjamin Djulbegovic, associate professor Interdisciplinary Oncology Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa. (Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers, 2008), William Comanor, professor of Public Policy and Corporate Management in the Aetna Chair, Emeritus, Harvard Kennedy School, University of California, “Mergers and Innovation in the Pharmaceutical Market” (2011).
During second half of the 20th century, the largest world pharmaceutical firms strongly developed, benefitting from a simple report: in the course of time, the human placed health at the top of his concerns.
Pushed by the world economic growth and the progressive globalization of exchanges, the pharmaceutical laboratories became important, financially powerful economic agents, and profiting from a worldwide presence. Today, this sector represents “more than 700 billion dollars, and its actors are, mainly, quoted on the Stock Exchange market” (Bailey, R. 2011)
However, the market of drugs and medical care is a difficult one. The insane growth of the Eighties and Nineties left the place to a fierce competition between the firms of the sector.
Our interest for this subject comes up to the fact that this end of the decade 2000 announces an historical turning point in the pharmaceutical market evolution. “The...
References: Bailey, R. (April, 2001). Reason Magazine: Damn the Pusher Man – Why does Everyone Seem to Hate the Pharmaceutical Industry?
Business Week (Jan 8, 2000)
Business Week (Jan 21, 2000). Are Mergers the Right Prescription for Drug Stocks?. [On-Line]. Available: Businessweek.com
Business Week (May 8, 2000)
Bancarel.J , (2003) « Fusions/acquisitions dans l 'industrie pharmaceutique ».
Deroïan.F ,M’chirgui.Z .Milelli.C. (2007) “Evidences on inter-firm R&D partnerships in three high-tech industries”, Working Paper 2007-24, EconomiX.
FierceBioTech, (2010) “Ten-Year Data on Pharmaceutical Mergers and Acquisitions, from DealSearchOnline.com”, Reveals Top Deals and Key Companies
Gulati.R., Nohria.N and Zaheer.A, (2000) “Strategic Networks”, Strategic Management Journal, 21.
Hamdouch a. and Depret m. H. (2001), La nouvelle économie industrielle de la pharmacie, Elsevier Paris.
Hite.J and Hesterly W (2001) “The evolution of firm networks: from emergence to early growth of the firm”, Strategic Management Journal, 22
Le Dortz.L,(2002) « Stratégies des fusions et acquisitions : pharmacie, chimie, matériels et services médicaux »
Leem, (May 2011) « En dix ans, la part de l 'Europe a beaucoup décru »
Nouvel observateur (le) [no 2410] (13/01/2011) « morts sur ordonnance - l 'industrie pharmaceutique - les mensonges de servier - mediator / l 'enquete des super-flics de la sante ».
Northrup.J, (2005), “The pharmaceutical sector", in Burns, L.R. (ed): The Business of healthcare inno-vation, Cambridge University press, Cambridge.”
OECD Publishing (March 2011) « Systèmes de santé : Efficacité et politiques »
Pfizer press release – (October 2009)
Remont S (2002)
Sultan-taïeb h. (2006) « Le rôle des alliances inter-entreprises dans les stratégies d’innovation des entreprises du secteur bio-pharmaceutique.
Seget.S. “Pharmaceutical strategic alliances”, Rapport Business Insights Ltd, Londres,
Takayama, (2011), « Refonte du Système des Visiteurs Médicaux & Industrie Pharmaceutique »
Wilson.S, (2008) “The elements of value network alliances: strategies for building alliance partnerships”. Deloitte Research.
Please join StudyMode to read the full document